- £162.55m
- £106.40m
- $255.10m
- 24
- 59
- 37
- 31
2019 December 31st | R2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | Interim Report | ARS | Interim Report | ARS |
Standards: | IFRS | — | IFRS | — | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 533 | 0.4 | 64.4 | 284 | 255 |
Cost of Revenue | |||||
Gross Profit | 223 | 0.4 | 12.7 | 89.1 | 75.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 379 | 131 | -875 | 413 | 347 |
Operating Profit | 155 | -130 | 940 | -128 | -91.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 120 | -157 | 874 | -141 | -102 |
Provision for Income Taxes | |||||
Net Income After Taxes | 119 | -157 | 870 | -172 | -143 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 93.6 | -394 | 895 | -62.7 | -144 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 93.6 | -394 | 895 | -62.7 | -144 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.214 | -0.991 | 1.23 | -1.29 | -0.554 |
Special Dividends per Share |